FBK Shorts Rise 47% in a Month Before Tuesday's Print
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

FB Financial Corporation reports Q3 results on Tuesday with a notable build-up in bearish positioning that stands in contrast to a broadly constructive analyst consensus.
The most striking feature of the current setup is the rapid growth of short interest. Shares short have climbed 47% over the past month to 4.9% of the free float, a meaningful move for a regional bank name. Despite that build, the borrow market remains under no real strain. Availability runs at roughly 1,065%, meaning there are around ten shares still available to borrow for every one currently shorted. Borrowing costs are low at 0.53%, though they have edged up about 8% over the past week. Options positioning tells a different story from the shorts: the put/call ratio is 0.11, essentially flat to its 20-day average and far below the 52-week high of 0.27, so options traders are not stacking up on downside protection. The stock itself has slipped 6% over the past month to $52.65, with peers including HWC, AUB and UBSI all down 1% to 3% on the week, suggesting the softness reflects sector-wide rate uncertainty rather than stock-specific selling.
Analysts are positioned well above where the stock is trading. The consensus price target is around $66, implying roughly 25% upside from current levels, and coverage is constructively skewed. Benchmark initiated with a Buy in June and lifted its target to $67 after last quarter's results. Raymond James carries a Strong Buy. The bull case rests on FB Financial's Southeastern franchise, particularly its Nashville exposure, where deposit growth reached $14.1 billion in Q1 with a 3.94% net interest margin and a CET1 ratio of 11.5%. Bears are focused on whether those metrics hold: the asset-sensitive balance sheet could see NIM pressure if rates move unfavourably, loan growth at an annualised 4% was characterised as the potential trough, and an unrealised loss on the securities book adds earnings sensitivity. The stock's P/E has compressed to around 10.4x, and price-to-book is 1.2x, both reasonable for a bank posting above-peer growth characteristics, but only if the growth story holds.
One genuinely notable detail on the register: Jonathan Ayers holds a Schedule 13D activist stake in FBK, a filing that signals active rather than passive intent. His most recent amendment, filed in May, shows a position of around 17,700 shares at a prior disclosure of 13.7% of the class. That said, 13D/G positions are event-driven disclosures around the 5% threshold; the current stake may differ materially from the last filing if he has been trading since May.
The recent insider activity is unremarkable in aggregate. The only open-market transaction of note in the past 90 days was a $413,000 sale by the Chief Accounting Officer in July, and the compensation-related share withholding entries from October are routine. Net insider activity is modestly negative on shares but not at a level that changes the picture.
Tuesday's print will test whether FB Financial can sustain the NIM expansion and deposit growth that justified the post-Q1 re-rating, and whether loan growth has found a floor or is still drifting lower.
Against its own history
This week's change in short interest is 2.1 standard deviations above the company's typical weekly move over the past year. Short interest is at its highest level in at least a year.
Against its peers
Shares moved -1.4% over the past week against a median of -2.2% for its closest peers.
Stocks in this article
See the live data behind this article on ORTEX.
Open FBK on ORTEX →How this article was generated
- Generated
- 12 Oct 2026, 04:07
- Data as of
- 12 Oct 2026, 04:01
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.